الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 188 |  |  |
| | | from | 188 | | |
Abstract
Introduction: The incidence of lung cancer continues to increase with approximately 175,000 new cases diagnosed annually in the United States. Lung cancer remains the number one cause of cancer related deaths in men and women. Although surgical resection remains the mainstay of therapy for early stage non–small cell lung cancer (NSCLC), most patients present with advanced disease. In addition, many patients with resectable early stage disease are unable to tolerate pulmonary resection because of compromised cardiopulmonary function. Recently, computerized tomography (CT)-guided percutaneous thermal ablation with radiofrequency ablation (RFA) has been introduced as an effective minimally invasive approach for the treatment of a variety of neoplasm including primary and secondary hepatic malignancies, and tumours located in bone, kidney, breast, brain, and lung Aim of work: This study was planned to evaluate the safety and efficacy of radiofrequency ablation in palliative treatment of peripheral non small cell lung cancer. Patients and methods: The study included 25 patients randomly selected and divided into 2 groups according to the modes of treatment: Group A; included 10 patients who were subjected to one session of radiofrequency ablation followed by systemic chemotherapy. Group B; included 15 patients who were subjected to systemic chemotherapy alone as a control group. All patients were subjected to the following: Medical history and clinical examination; Laboratory investigations: (CBC, liver functions tests, kidney function tests, coagulation profile and ABGs). Radiological investigations; Fiberoptic bronchoscopy; Pulmonary function tests and TNM staging Results: The mean age of patients treated with RFA (group A) was 58.4 years ± 8.12 (9 males and one female), while for group B it was 56.5 years ± 9.16 (13 males and 2 female), the 2 groups were age and sex matched (P = 0.607 and 0.802 respectively). The cell types in group A were as following: 4 patients; squamous cell carcinoma, 5 patients; adenocarcinoma and one patient; large cell carcinoma, while in group B: 8 patients; squamous cell carcinoma, 14 patients; adenocarcinoma and 3 patients; large cell carcinoma. Before the start of treatment there was no statistically significant difference between both groups as regard the mean of tumor size (P = 0.380), symptoms scoring (chest pain, cough and haemoptysis) (P = 0.18, 0.328 and 0.893 respectively) and the Karnofsky scale (P =0.373). Conclusions: Radiofrequency ablation is an adjuvant effective and safe modality with minimal side effects as a palliative treatment for patients with inoperable peripherally located non-small cell lung cancer. Efficacy of RFA is better for smaller compared to larger tumors. CT chest is a reliable method for assessing the precise therapeutic efficacy of radiofrequency ablation during follow up. Combination of radiofrequency ablation and chemotherapy may improve the survival rate and quality of life.